BioXcelerate introduces an innovative AI tool for drug discovery

Optima Partners' health data science division, bioXcelerate, has recently unveiled a new tool designed to expedite the drug discovery process.

In a press release dated March 20, 2024, the e health data science division of Optima Partners Limited, bioXcelerate, unveiled PleioGraph, an innovative artificial intelligence (AI) tool. PleioGraph aims to enhance the efficiency of the drug discovery process.

By utilizing the company's proprietary machine learning algorithms, PleioGraph offers assistance to drug developers in identifying genetic colocalization. This crucial process involves the interaction of genes, proteins, and cells, which ultimately leads to the development of diseases. By sharing this information, drug developers can gain valuable insights into the development of diseases, ultimately helping to accelerate the drug development process.

The amount of data that is now accessible is surpassing our capacity to analyze it. Although there is a wealth of data available, the availability of AI technologies that can efficiently and accurately uncover the underlying patterns of disease is limited. At bioXcelerate, we offer a solution to address these challenges. By leveraging our extensive academic expertise and vast knowledge in health data science, our PleioGraph technology offers a cutting-edge tool to enhance early-phase drug discovery and ultimately enhance patient outcomes.

The global pharmaceutical industry reported a total expenditure of $244 billion on research and development in 2022. Nevertheless, research conducted by Deloitte reveals that the return on investment from R&D in 2022 has reached its lowest level at 1.2%. In addition, there has been an increase in both the average time and cost of developing a new drug.

The costs of drug development have been increasing, and when combined with a significant failure rate, the process of creating new treatments has become lengthy and expensive. Through the enhancement of drug discovery processes, there is potential to expedite the development of new medications that have a positive effect on patients' well-being and can be made available more quickly.
BioXcelerate, an impressive health data division of Optima Partners, was established by esteemed academics hailing from renowned universities in the United Kingdom, such as Cambridge, Edinburgh, Imperial College, and Oxford.

The company is dedicated to leveraging data science to enhance the pharmaceutical, biotech, and public health sectors. Our goal is to improve patient outcomes by accelerating drug discovery and clinical development processes through the application of advanced statistics, machine learning, and software engineering.

Source: bioXcelerate; Statista; Deloitte